**Executive Summary**
This report details the progress of the Indian Government’s initiatives to strengthen the pharmaceutical industry through the PLI, PRIP, and PMBJP schemes as of December 2025. It highlights a budgetary commitment exceeding ₹11,000 crore to enhance self-reliance in bulk drug manufacturing, foster innovation through research centers, and provide affordable generic medicines to citizens. Key milestones include the commissioning of 38 greenfield projects and the establishment of seven Centres of Excellence.
**Key Points / Main Content**
**Production Linked Incentive (PLI) Scheme for Bulk Drugs**
* **Budget and Objective:** Launched with an outlay of ₹6,940 crore to promote domestic manufacturing of Key Starting Materials (KSMs), Drug Intermediates (DIs), and Active Pharmaceutical Ingredients (APIs).
* **Implementation Status:** As of December 2025, 48 greenfield projects have been approved with a committed investment of ₹4,329.95 crore.
* **Actual Progress:** Actual investment has reached ₹4,814.1 crore, with 38 projects already commissioned.
* **Capacity:** The commissioned projects have established a domestic manufacturing capacity of approximately 56,800MT per annum.
**Promotion of Research and Innovation in Pharma MedTech Sector (PRIP)**
* **Innovation Focus:** A ₹5,000 crore scheme designed to shift the sector from cost-based to innovation-based growth through industry-academia linkages.
* **Infrastructure:** Seven Centres of Excellence (CoEs) have been established with a budgetary support of ₹700 crore.
* **Research Output:** CoEs have approved 104 research projects and filed two patents to date.
* **Support for Startups:** ₹4,250 crore is allocated specifically to support industry and startups for R&D in priority areas such as medical devices and drug discovery.
**Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)**
* **Affordability:** Provides generic medicines at prices 50% to 80% cheaper than branded alternatives via Jan Aushadhi Kendras (JAKs).
* **Regional Reach:** Significant implementation in Madhya Pradesh (634 JAKs) and the Union Territory of Dadra and Nagar Haveli and Daman & Diu (41 JAKs).
* **Supply Chain Management:** The Pharmaceutical & Medical Devices Bureau of India (PMBI) uses an IT-enabled system to monitor stocks.
* **Product Monitoring:** JAKs are incentivized to maintain stocks of 200 high-demand products, while 400 fast-moving products are monitored via digital forecasting.
**Impact Analysis**
**Pharmaceutical Manufacturers**
**Impact**
Companies benefit from financial incentives and a structured framework to establish greenfield projects for bulk drugs, reducing their dependence on imports.
**Action Required**
Approved companies must meet their committed investment targets and complete the commissioning of manufacturing units as per the scheme's guidelines.
**Research Institutions and Startups**
**Impact**
Stakeholders gain access to advanced research infrastructure through Centres of Excellence and significant funding for innovation-based projects.
**Action Required**
Collaborate with academia and industry to undertake R&D in identified priority areas and apply for project approvals under the PRIP scheme.
**General Public (Patients)**
**Impact**
Citizens experience a substantial reduction in healthcare out-of-pocket expenses due to the availability of high-quality, low-cost generic medicines.
**Action Required**
Utilize the network of Jan Aushadhi Kendras to access affordable healthcare products.
**Implementing Agencies (PMBI)**
**Impact**
The agency is responsible for the end-to-end management of the medicine supply chain using digital tools.
**Action Required**
Maintain regular monitoring and periodic forecasting of fast-moving products to prevent stockouts at JAKs.
Key Entities Referenced
PLI Scheme for Bulk Drugs: A production-linked incentive scheme with a ₹6,940 crore outlay to promote domestic manufacturing of critical Key Starting Materials, Drug Intermediates, and Active Pharmaceutical Ingredients.
Promotion of Research and Innovation in Pharma MedTech Sector (PRIP): A ₹5,000 crore scheme focused on transforming India's Pharma MedTech sector through industry-academia research linkages and the establishment of Centres of Excellence.
Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP): A government initiative aimed at providing quality generic medicines at affordable prices through a nationwide network of Jan Aushadhi Kendras.
Pharmaceutical & Medical Devices Bureau of India (PMBI): The implementing agency for the PMBJP scheme responsible for managing the IT-enabled supply chain and monitoring medicine availability.
Department of Pharmaceuticals: The primary government department under the Ministry of Chemicals and Fertilizers responsible for the policy and implementation of the pharmaceutical industry schemes.
Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals
Establishment of Pharmaceutical Industry
Posted On: 27 MAR 2026 4:23PM by PIB Delhi
The Government has launched the PLI Scheme for promotion of domestic manufacturing of critical Key
Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in
India (also known as the PLI Scheme for Bulk Drugs) to promote the establishment of new
pharmaceutical industrial units. The PLI Scheme for Bulk Drugs has a budgetary outlay of ₹6,940 crore,
and it aims to improve self-reliance and reduce import dependence in critical KSMs, DIs and APIs. As of
December 2025, 48 greenfield projects have been approved under the scheme with committed investment
of ₹4,329.95 crore, against which actual investment of ₹4,814.1 crore has been made. 38 projects have
been commissioned, resulting in establishment of domestic manufacturing capacity of approximately
56,800MT per annum. Details of projects approved under PLI Scheme for Bulk Drugs, State-wise and
district-wise are placed at Annexure.
The Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme has been launched
by the Government with an outlay of ₹5,000 crore to transform India’s Pharma MedTech sector including
Madhya Pradesh and Dadra and Nagar Haveli, from cost-based to innovation-based growth by
strengthening research and to promote industry-academia linkage for research and development in priority
areas in drug discovery and development and medical devices. Under this, seven Centres of Excellence
(CoEs) have been set up, with total budgetary support to the tune of ₹700 crore, to create research
infrastructure and promote R&D in identified areas. The CoEs have so far approved 104 research projects
under the scheme and have filed two patents. The scheme also includes an outlay of ₹4,250 crore for
support to industry and startups, including in collaboration with academia, for undertaking research and
innovation projects in priority areas.
The Pradhan Mantri Bhartiya Janaushadhi Pariyojana was launched by the Government of India to make
quality generic medicines available at affordable prices for all citizens. Under this scheme, special outlets
called Jan Aushadhi Kendras are opened across the country which provide medicines that are about 50%
to 80% cheaper than branded medicines, helping reduce healthcare expenses for patients. Under the
scheme, 634 JAKs in Madhya Pradesh and 41 JAKs in the Union Territory of Dadra and Nagar Haveli and
Daman & Diu have been opened which aim to increase the availability of affordable medicines in Madhya
Pradesh and Union Territory of Dadra and Nagar Haveli and Daman & Diu. Further, to increase
availability of medicines, Pharmaceutical & Medical Devices Bureau of India (PMBI), which is the
implementing agency of the PMBJP scheme, utilises an end-to-end information-technology-enabled
supply chain system through which availability of medicines are monitored in these JAKs. The JAKs are
incentivised to maintain the stocks of 200 high demand products under the scheme. In addition, 400 fast-
moving products are monitored regularly by PMBI with periodic forecasting aided by digital tools.
Annexure
Details of approved projects under the PLI Scheme for Bulk Drugs, State-wise and district-wise:S. Name of the Company Product District Project Location
No. (State)
1. Aurobindo Pharma Penicillin G East Godavari Andhra Pradesh
Limited Through Lyfius
Pharma Pvt Ltd.
2. Karnataka Antibiotics and 7 ACA Ujjain Madhya Pradesh
Pharmaceuticals Limited
3. Kinvan Private Limited Clavulanic Acid Solan Himachal Pradesh
4. Orchid Bio-Pharma 7 ACA Kathua Jammu & Kashmir
Limited
5. Macleods Pharmaceutical Rifampicin Bharuch Gujarat
Limited
6. Natural Biogenex Private Betamethasone Tumkur Karnataka
Limited
7. Natural Biogenex Private Dexamethasone Tumkur Karnataka
Limited
8. Natural Biogenex Private Prednisolone Tumkur Karnataka
Limited
9. Symbiotec Pharmalab Prednisolone Dhar Madhya Pradesh
Private Limited
10. Emmennar Pharma Pvt 1,1 Cyclohexane Sangareddy Telangana
Ltd. Diacetic Acid (CDA)
11. Granules India Limited Dicyandiamide Visakhapatnam & Andhra Pradesh
(DCDA) Kakinada (2
locations)
12. Hindys Lab Pvt Ltd. 1,1 Cyclohexane Nalgonda Telangana
Diacetic Acid (CDA)
13. Meghmani LLP Para Amino Phenol Bharuch Gujarat
14. Sadhana Nitro Chem Ltd. Para Amino Phenol Raigad Maharashtra
15. Alta Laboratories Limited Aspirin Raigad Maharashtra16. Amoli Organics Private Diclofenac Sodium Valsad Gujarat
Limited
17. Anasia Lab Private Losartan Nalgonda Telangana
Limited
18. Anasia Lab Private Olmesartan Nalgonda Telangana
Limited
19. Andhra Organics Limited Olmesartan Srikakulam Andhra Pradesh
20. Andhra Organics Limited Sulfadiazine Srikakulam Andhra Pradesh
21. Andhra Organics Limited Telmisartan Srikakulam Andhra Pradesh
22. Aviran Pharmachem Artesunate Mehsana Gujarat
Private Limited
23. Centrient Pharmaceuticals Atorvastatin Nawanshahr Punjab
India Private Limited
24. Dasami Lab Pvt Ltd. Carbamazepine Nalgonda Telangana
25. Dasami Lab Pvt Ltd. Oxcarbazepine Nalgonda Telangana
26. Global Pharma Healthcare Ofloxacin Tiruvannamalai Tamil Nadu
Private Limited
27. Globela Industries Pvt Ltd Norfloxacin Bharuch Gujarat
28. Globela Industries Pvt Ltd Ofloxacin Bharuch Gujarat
29. Hazelo Lab Pvt Ltd. Vitamin B6 Yadadri Telangana
30. Hetero Drugs Limited Carbidopa Visakhapatnam Andhra Pradesh
31. Hetero Drugs Limited Levodopa Visakhapatnam Andhra Pradesh
32. Hetero Drugs Limited Levofloxacin Sangareddy Telangana
33. Hetero Drugs Limited Oxcarbazepine Sangareddy Telangana
34. Hindys Lab Pvt Ltd. Acyclovir Nalgonda Telangana35. Honour Lab Limited Levetiracetam Sangareddy Telangana
36. Honour Lab Limited Lopinavir Visakhapatnam Andhra Pradesh
37. Honour Lab Limited Valsartan Sangareddy Telangana
38. Honour Lab Limited Vitamin B6 Visakhapatnam Andhra Pradesh
39. K P Manish Global Artesunate Cuddalore Tamil Nadu
Ingredients Pvt Ltd.
40. Kreative Actives Private Diclofenac Sodium Visakhapatnam Andhra Pradesh
Limited
41. MSN Life Sciences Pvt Levofloxacin Medak Telangana
Ltd.
42. RMC Performance Aspirin Jalgaon Maharashtra
Chemicals Private Limited
43. Sudarshan Pharma Vitamin B1 Raigad Maharashtra
Industries Ltd. (Chemical Synthesis
Route)
44. Sudarshan Pharma Vitamin B6 Raigad Maharashtra
Industries Ltd.
45. Vital Laboratories Private Levofloxacin Valsad Gujarat
Limited
46. Vital Laboratories Private Ofloxacin Valsad Gujarat
Limited
47. Sustainable Environment Erythromycin SAS Nagar Punjab
Developers Limited Thiocynate (TIOC)
48. Orgo Pharma and Fuels 2-Methyl-5Nitro- Yamuna Nagar Haryana
LLP Imidazole (2-MNI)
This information was given by Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a
written reply in the Lok Sabha today.
*****
PC/PM(Release ID: 2246061) Visitor Counter : 68